News-Medical.Net February 16, 2025
Biophysical Society

In diseases like Parkinson’s and Alzheimer’s, specific proteins misfold and clump together, forming toxic aggregates that damage brain cells. The process of proteins spontaneously clumping is called protein aggregation and researchers have developed novel methods to generate aggregate-specific antibodies as specific probes or modulators of the aggregation process.

This new method overcomes significant challenges in characterizing these complex and often transient protein structures. The work will be presented at the 69th Biophysical Society Annual Meeting, to be held February 15 – 19, 2025 in Los Angeles.

Most pathological aggregates, called oligomers, are difficult to study with traditional methods, due to their fleeting nature and structural variability. Antibodies, known for their precise target binding, offer a powerful tool for investigating these...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Stakeholder Management and Interoperability of Biosimilars
Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million
Pharma Pulse 2/21/25: RWE in Medical Research and Drug Development, Inhaled Antibody Therapy for RSV & more
FDA approves first rapid-acting insulin biosimilar for diabetes

Share This Article